Recent News

• 05.26.2026 - Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
• 05.14.2026 - Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
• 04.30.2026 - Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
• 04.28.2026 - Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
• 04.22.2026 - Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
• 04.20.2026 - Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
• 03.18.2026 - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Recent Filings

• 05.14.2026 - 8-K Current report
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.11.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.30.2026 - 8-K Current report
• 04.29.2026 - DEF 14A Other definitive proxy statements
• 04.29.2026 - ARS Annual Report to Security Holders
• 04.28.2026 - 8-K Current report
• 04.21.2026 - EX-99.1 EX-99.1
• 04.21.2026 - 8-K Current report
• 04.17.2026 - PRE 14A Other preliminary proxy statements